12-Jan-2026
Sensus Healthcare to Hold Investor Meetings During JPM Week 2026 in San Francisco
Business Wire (Wed, 7-Jan 4:30 PM ET)
Sensus Healthcare Appoints Larry Biscotti to its Board of Directors
Business Wire (Wed, 7-Jan 8:30 AM ET)
Sensus Healthcare Expands Role of President Michael Sardano to Include Chief Commercial Officer
Business Wire (Fri, 14-Nov 8:00 AM ET)
Sensus Healthcare Appoints Eric Sachetta to its Board of Directors
Business Wire (Wed, 12-Nov 8:00 AM ET)
Sensus Healthcare Reports Third Quarter 2025 Financial Results
Business Wire (Thu, 6-Nov 4:05 PM ET)
Sensus Healthcare Named to TIME's America's Growth Leaders of 2026
Business Wire (Thu, 6-Nov 8:00 AM ET)
CMS Validates Sensus SRT: Major Coding Update Enhances Reimbursement and Expands Patient Access
Market Chameleon (Tue, 4-Nov 5:35 AM ET)
CMS Establishes Coding Validating Sensus SRT for Treating Non-Melanoma Skin Cancer
Business Wire (Tue, 4-Nov 8:00 AM ET)
Sensus Healthcare Announces the Passing of Director Bill McCall
Business Wire (Fri, 31-Oct 8:00 AM ET)
Business Wire (Thu, 23-Oct 8:00 AM ET)
Sensus Healthcare Inc is engaged in manufacturing a superficial radiotherapy system. These devices are used for treating both oncological and non-oncological skin conditions including basal cell and squamous cell skin cancers and other skin conditions such as keloids. Its product includes SRT-100, SRT-100 vision, and a sentinel service program. The company's revenue is generated majorly from customers in the United States.
Sensus Healthcare trades on the NASDAQ stock market under the symbol SRTS.
As of January 12, 2026, SRTS stock price declined to $4.61 with 49,274 million shares trading.
SRTS has a beta of 0.12, meaning it tends to be less sensitive to market movements. SRTS has a correlation of 0.00 to the broad based SPY ETF.
SRTS has a market cap of $75.72 million. This is considered a Micro Cap stock.
Last quarter Sensus Healthcare reported $7 million in Revenue and -$.06 earnings per share. This beat revenue expectation by $1 million and exceeded earnings estimates by $.05.
In the last 3 years, SRTS traded as high as $9.62 and as low as $1.79.
The top ETF exchange traded funds that SRTS belongs to (by Net Assets): VTI, VXF, DFSV, DFAS, IWC.
SRTS has underperformed the market in the last year with a return of -32.5%, while SPY returned +19.2%. This shows that you would have done better investing in the overall market (through SPY) over the last year than in SRTS shares. However, SRTS has outperformed the market in the last 3 month and 2 week periods, returning +35.6% and +21.6%, while SPY returned +3.9% and +0.7%, respectively. This indicates SRTS has been having a stronger performance recently.
SRTS support price is $4.55 and resistance is $4.97 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SRTS shares will trade within this expected range on the day.